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Abstract
The least toxic time (LTT) of irinotecan varied by up to 8 hours according to sex 
and genetic background in mice. The translational relevance was investigated 
within a randomized trial dataset, where no LTT stood out significantly in the whole 
population.
130 male and 63 female eligible patients with metastatic colorectal cancer were randomized 
to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered 
by 4 hours on day 1, then fixed-time chronomodulated Fluorouracil-Leucovorin-Oxaliplatin 
for 4 days, q3 weeks. The sex-specific circadian characteristics of grade (G) 3-4 toxicities were 
mapped with cosinor and time*sex interactions confirmed with Fisher's exact test.
Baseline characteristics of male or female patients were similar in the six treatment groups. 
Main grade 3-4 toxicities over six courses were diarrhea (males vs females, 39.2%; vs 46.0%), 
neutropenia (15.6% vs 15.0%), fatigue (11.5% vs 15.9%), and anorexia (10.0% vs 7.8%). They 
were reduced following irinotecan peak delivery in the morning for males, but in the after-
noon for females, with statistically significant rhythms (P < .05 from cosinor) and sex*timing 
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1 |  INTRODUCTION
Up to fivefold differences in systemic or tissue-specific tox-
icities have been shown as a function of timing of administra-
tion for 50 anticancer drugs in experimental models.1-4 The 
rhythms in anticancer drugs pharmacology are controlled by 
molecular clocks, whose suppression impairs the therapeutic 
benefits due to optimal treatment timing.5,6 For instance, the 
lethal toxicity of irinotecan, a topoisomerase I inhibitor, was 
twice as large in male mice dosed at night, that is, near the 
middle of their nocturnal activity span, as compared to drug 
dosing in the second half of their resting span during day-
time.7 Subsequent studies, however, revealed that the least 
toxic time of administration of irinotecan occurred about 
6  hours later in female mice as compared to male mice.8 
Additionally, large sex-dependent differences in irinotecan 
chronopharmacology and chronotoxicity were observed and 
predicted by the reciprocal transcription dynamics of core 
clock genes Bmal1 and Rev-Erbα.8,9 Moreover, clinical ev-
idence for sex-related risk of toxicity on irinotecan and other 
drugs has been reported.10-13 The triplet combination of irino-
tecan (I), 5-Fluorouracil-Leucovorin (FL), and Oxaliplatin 
(O), including its chronomodulation (chrono), has fostered 
forefront medico-surgical strategies and enhanced survival 
and cures in patients with metastatic colorectal or pancreatic 
cancers.14-18 Nonetheless, the toxicity rates of such triplet 
combinations are nearly twice as large as those from dou-
blets15 especially in female patients.19
Moreover, the efficacy of a fixed chronoFLO schedule 
prolonged overall survival as compared to constant rate FLO 
or FOLFOX in male but not in female patients.20 Neutropenia 
was halved on chronoFLO, yet being worse in female as com-
pared to male patients on either schedule.21 In a time-find-
ing study comparing eight time-lagged chronoFLO protocols 
in metastatic colorectal cancer patients, toxicity was nearly 
twice as large in female as compared to males. Moreover, op-
timal chemotherapy timing occurred 6 hours later in women 
as compared to men.22 The combination of irinotecan and 
chronoFLO proved to be active and safe in patients with col-
orectal cancer.23,24 The current international, randomized, 
controlled, multi-arm, time-finding study aimed at the deter-
mination of the least toxic time of irinotecan, based on an ex-
pected rate of severe toxicities in 40% to 80% of the patients 
and no sex differences in time-related toxic events.25 None of 
these hypotheses was validated, and their adequacy was sub-
sequently questioned by preclinical and clinical reports.8-13 
Here, we show that irinotecan tolerability was largely and 
significantly improved following its delivery in the morning 
for males and in the afternoon for females with metastatic 
colorectal cancer.
2 |  PATIENTS AND METHODS
2.1 | Patients
Adult patients with histologically proven, measurable and 
unresectable advanced colorectal cancer were eligible, if 
having a Performance Status (PS) of 0-2, according to the 
classification of the World Health Organisation. They could 
have received up to one previous chemotherapy protocol 
(Supplementary text). All enrolled patients provided signed 
informed consent.
2.2 | Study design
The protocol was approved by the three National Ethical 
Review Boards, and abided by the Helsinki Declaration's 
recommendations.26 The main objective was to assess the 
role of the time of irinotecan delivery, combined with fixed-
time chronoFLO.24 It was hypothesized that irinotecan tim-
ing would account for a 15% difference in the rate of patients 
with at least one toxicity-related dose reduction or treatment 
delay over the initial three courses of chemotherapy irrespec-
tive of sex or prior treatment. It was calculated that the ran-
dom allocation of 30 patients in each of the six corresponding 
irinotecan timing groups would enable the estimation of the 
least toxic time of irinotecan with 95% Confidence Interval 
of <6 hours, using a logistic regression model.27
interactions (Fisher's exact test, diarrhea, P = .023; neutropenia, P = .015; fatigue, P = .062; 
anorexia, P = .032). Irinotecan timing was most critical for females, with grades 3-4 ranging 
from 55.2% of the patients (morning) to 29.4% (afternoon) for diarrhea, and from 25.9% (morn-
ing) to 0% (afternoon) for neutropenia.
The study results support irinotecan administration in the morning for males and in the after-
noon for females, in order to minimize adverse events without impairing efficacy.
K E Y W O R D S
chronotherapy, circadian, colorectal cancer, gender, irinotecan, toxicity
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Patients were randomized to receive irinotecan (180 mg/
m2) as a 6-hours chronomodulated infusion, with peak deliv-
ery times scheduled at 01:00, 05:00, 09:00, 13:00, 17:00, or 
21:00 (Figure 1). All treatments were administered to non-
hospitalized patients using a programmable-in time, ambula-
tory infusion pump (Melodie, Aguettant).
Randomization was performed at the EORTC Data Center, 
with a minimization technique used for treatment allocation, 
stratifying by institution, PS (0-1 vs 2), and line of treatment 
(1st vs 2nd), but not sex. Treatment allocation was indicated 
to the center following patient registration.
Hematological toxicity was assessed with weekly blood 
cell counts. Clinical and biochemical toxicities were as-
sessed and graded according to the NCIC CTAE v2 crite-
ria every 3 weeks. Treatment responses were assessed every 
third course based on computed thoraco-abdomino-pelvic 
F I G U R E  1  Graphical representations 
of the six treatment schemes compared. 
The triplet combinations consisted of day 
1 chronomodulated irinotecan (180 mg/
m2) over 6 h with 1 of 6 possible clock 
hours for infusion onsets and peak delivery 
rates (black, striped), followed by the 
same fixed time chronoFLO schedule. The 
latter involved days 2-5 chronomodulated 
5-fluorouracil-leucovorin from 22:15 to 
9:45 (white and light gray, respectively), 
alternating with Oxaliplatin from 10:15 to 
21:45 (dark gray) over 4 d. Cumulated doses 
per course were 2.8 g/m2 for 5-Fluorouracil, 
1.2g/m2 for leucovorin, and 80 mg/m2 for 
oxaliplatin. Courses were repeated every 
21 d, that is, after a 16 d' interval. The 
abscissa indicates actual clock hours and 
days
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tomography scan, and other relevant imaging techniques. 
Protocol treatment was to be continued until disease progres-
sion or confirmed complete response, treatment intolerance, 
or patient refusal (see also Supplementary Text about Trial 
Methods).
2.3 | Endpoints
The primary endpoint of the trial was the proportion of patients 
presenting any clinical or hematological toxicity graded ac-
cording to the Common Toxicity Criteria for Adverse Events 
v2 and requiring dose reduction or treatment delay, over 
the initial three courses, as a function of irinotecan timing. 
Objective responses (ORs) were assessed with the RECIST 
v1.1 criteria.28 The current report evaluates these outcomes 
separately in men and women, based on recent preclinical 
results and data from earlier clinical studies.20
2.4 | Statistical analysis
Here, we first considered the proportions of male or female 
patients who experienced grade 3-4 or grade 2-4 toxicities 
within a given irinotecan timing schedule over the initial 
three or six cycles. We graphically displayed the sex-specific 
relative changes for each main toxicity endpoint using a 
heat map, in order to visualize any consistent 24-hour pat-
tern across different toxicity endpoints for each sex. We then 
analyzed these data with cosinor.29 This nonlinear technique 
involved the fitting of a cosine curve with a period of 24 and/
or 12 hours to the distribution of the toxicity data according 
to irinotecan peak delivery timing.29 The program computed 
the mesor (rhythm-adjusted mean), the amplitude (half of the 
extent of the predictable change of the modeled curve) and 
the acrophase and bathyphase (respective times of peak and 
through of the modeled curve) with their respective 95% con-
fidence limits. For each toxicity endpoint, F-tests were used 
to determine the best-fit model between (a) a flat line (ie, no 
rhythm) (b) a cosine curve with a period of 24-hours with 
a 12-hour harmonic, (c) a purely 24-hour cosine curve, (d) 
a purely 12-hour cosine curve. Statistical significance level 
was set to P < .05. This was programmed using Matlab (The 
Mathworks, Inc).
Clinically relevant implications were visually highlighted 
further through pooling toxicity or efficacy data correspond-
ing to irinotecan dosing in the morning (peak delivery time 
at 05:00 or 09:00; midpoint, 07:00), in the afternoon (peak 
delivery time at 13:00 or 17:00; midpoint, 15:00) or at night 
(peak delivery time at 21:00 or 01:00; midpoint, 23:00), sep-
arately for male and female patients. Sex*irinotecan timing 
interactions were further analyzed using Chi-Square and 
Fisher's exact  test. All toxicity analyses were performed on 
the treated and evaluated patients. Efficacy was assessed in 
the eligible patient population using SPSS v24 (IBM Inc). 
Statistical significance level was set at P < .05.
3 |  RESULTS
3.1 | Patient characteristics
From February 2002 to August 2006, 199 patients were 
enrolled at 18 institutions in Belgium, France or Italy, and 
randomized to one of the six treatment groups as planned 
(Figure 2). The eligible study population involved 193 pa-
tients (97%). Two eligible patients received irinotecan ac-
cording to a protocol modality that differed from the one 
assigned by randomization and were reallocated to the real 
treatment timing group. ChronoIFLO was administered as 
first-line treatment to 149 patients (77.2%) and as second line 
to 44 patients (22.8%). The main clinical and demographic 
features of the eligible patient population were similar in the 
six treatment groups. Overall, study participants included 130 
males and 63 females, with a PS of 0 for 142 patients (73.5%) 
and a median age of 61 years (range: 29-80). There were 18 
to 24 males and 7 to 15 females in each treatment modal-
ity, with similar clinical characteristics among each treatment 
modality (Table 1). Likewise, the occurrence of comorbidi-
ties, the incidence of metastatic stage at diagnosis and the 
proportion of patients having received adjuvant chemother-
apy were comparable in both men and women among the six 
treatment groups (data not shown). Nonsignificant imbal-
ances were seen for the percentages of patients with two or 
more metastatic sites.
3.2 | Overall treatment toxicities and dose 
intensities
Four patients died during the initial 2 months (2.1%), includ-
ing two toxic deaths (1%). A 76 y.o male patient died with 
grade 5 diarrhea after the first course involving irinotecan 
peak delivery at 01:00; a 50  y.o. male patient died with a 
grade 5 gastro-intestinal fistula and circulatory collapse after 
two courses where irinotecan peak delivery was scheduled 
at 17:00. The Independent Data Monitoring Committee con-
firmed the safety of the protocol, with an observed toxic-
ity not exceeding the expected range after inclusion of 100 
patients.
A total of 1,138 courses were administered, with a me-
dian of six per patient (range: 1 to 18). The analysis of the 
drug delivery report outputs revealed the occurrence of pump 
dysfunction resulting in underdosing for 2.8% of the courses. 
The main reasons for protocol discontinuation were toxicity 
(37.8%), disease progression (23.8%), complete response 
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after surgery of metastases (10.9%), or patient refusal (8.3%). 
Three or more protocol courses were administered to 82.3% 
of the male patients, and 82.5% of the female patients, with-
out any obvious difference according to treatment group 
(Table S1).
Over the initial six treatment courses, grades 3-4 diar-
rhea was reported for 51/130 men (39.2%) and 29/63 women 
(46%). Grades 3-4 neutropenia was encountered in 20/128 
men (15.6%) and 9/60 women (15%) (NS). Grade 3 fatigue 
was experienced by 15/130 men (10%) and 10/63 women 
(15.9%). Grade 3 anorexia occurred in 13/130 men (10%) and 
5/63 women (7.9%), while grade 3-4 anemia was found for 
6/60 women (10%), as compared to 1/127 men (0.8%).
Median dose intensities (mg/m2/week) were 53 for 
irinotecan, 24 for oxaliplatin, and 853 and 199 for 5-flu-
orouracil and leucovorin over the whole treatment span, 
and without any significant difference according to sex 
and prior chemotherapy (not shown). These figures corre-
sponded to actual relative dose intensities > 70% of those 
planned for 93.4% to 94.9% of the patients according to the 
drug considered.
The percentages of patients withdrawn for toxicity ac-
cording to irinotecan timing had a similar range in males 
(from 25% to 47.8%) and in females (from 28.6% to 50%), 
This rate was highest at 17:00 for male patients, as compared 
to 09:00 for female patients (Table S1).
3.3 | Relevance of irinotecan timing 
according to sex
As shown in heatmap graphs (Figure 3A), grade 3-4 leuko-
penia and neutropenia were worst in the male patients re-
ceiving irinotecan with peak delivery time at 21:00 and least 
at 13:00 over the initial three or six courses. In contrast for 
the female patients, the most toxic times corresponded to 
05:00 or 09:00, while treatment was least hematotoxic fol-
lowing irinotecan delivery with peak rate at 17:00. Clinical 
F I G U R E  2  CONSORT diagram. Six patients were ineligible because of concomitant cancer or inappropriate cancer staging
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T A B L E  1  Main clinical features of the eligible study population, separately according to sex and to randomized treatment modality as 
defined by timing of irinotecan peak delivery rate
Males Modality
All
N = 130
01:00
n = 22
05:00
n = 19
09:00
n = 18
13:00
n = 24
17:00
n = 23
21:00
n = 24 P-value
Age, (y)
Median (range) 62 (33-80) 64 (51-76) 62 (46-80) 60 (45-70) 62.5 (33-77) 62 (50-79) 61.5 (38-71) .492
PS (WHO)
0 97 (74.6%) 14 (63.6%) 16 (84.2%) 14 (77.8%) 15 (62.5%) 20 (87.0%) 18 (75.0%)
1 29 (22.3%) 7 (31.8%) 3 (15.8%) 3 (16.7%) 8 (33.3%) 2 (8.7%) 6 (25.0%)
2 4 (3.1%) 1 (4.5%) 0 1 (5.6%) 1 (4.2%) 1 (4.3% 0 .441
Site of primary tumor
Colon 104 (80.0%) 17 (77.3%) 17 (89.5%) 16 (88.9%) 19 (79.2%) 16 (69.6%) 19 (79.2%)
Rectum 26 (20.0%) 5 (22.7%) 2 (10.5%) 2 (11.1%) 5 (20.8%) 7 (30.4%) 5 (20.8%) .691
Prior chemotherapy
No 97 (74.6%) 18 (81.8%) 13 (68.4%) 14 (77.8%) 17 (70.8%) 18 (78.3%) 17 (70.8%) .906
N of sites involved
1 66 (50.8%) 8 (36.4%) 15 (78.9%) 8 (44.4%) 12 (50.0%) 11 (47.8%) 12 (50.0%)
2 43 (33.1%) 7 (31.8%) 2 (10.5%) 9 (50.0%) 7 (29.2%) 9 (39.1%) 9 (37.5%)
3 or more 21 (16.2%) 7 (31.8%) 2 (10.5%) 1 (5.6%) 5 (20.8%) 3 (13.0%) 3 (12.5%) .168
Sites involved
Liver only 49 (37.7%) 8 (36.4%) 13 (68.4%) 4 (22.2%) 7 (29.2%) 7 (30.4%) 10 (41.7%)
Liver + other 59 (45.4%) 12 (54.5%) 3 (15.8%) 10 (55.6%) 11 (45.8%) 12 (52.2%) 11 (45.8%)
Other only 22 (16.9%) 2 (9.1%) 3 (15.8%) 4 (22.2%) 6 (25.0%) 4 (17.4%) 3 (12.5%) .173
Females Modality
All
N = 63
01:00
n = 10
05:00
n = 15
09:00
n = 14
13:00
n = 9
17:00
n = 8
21:00
n = 7 P-value
Age, years
Median (range) 58 (29-77) 58.5 (35-77) 59 (31-70) 56 (49-76) 58 (34-70) 51.5 (42-74) 54 (29-70) .741
PS (WHO)
0 45 (71.4%) 9 (90.0%) 9 (60.0%) 9 (64.3%) 7 (77.8%) 6 (75.0%) 5 (71.4%)
1 15 (23.8%) 1 (10.0%) 5 (33.3%) 5 (35.7%) 1 (11.1%) 1 (12.5%) 2 (28.6%)
2 3 (4.8%) 0 1 (6.7%) 0 1 (11.1%) 1 (12.5%) 0 .666
Site of primary tumor
Colon 49 (77.8%) 8 (80.0%) 11 (73.3%) 12 (85.7%) 6 (66.7%) 6 (75.0%) 6 (85.7%)
Rectum 14 (22.2%) 2 (20.0%) 4 (26.7%) 2 (14.3%) 3 (33.3%) 2 (25.0%) 1 (14.3%) .642
Prior chemotherapy
No 52 (82.5%) 8 (80.0%) 13 (86.7%) 11 (78.6%) 7 (77.8%) 7 (87.5%) 6 (85.7%) .988
N of sites involved
1 27 (42.9%) 3 (30.0%) 3 (20.0%) 6 (42.9%) 6 (66.7%) 4 (50.0%) 5 (71.4%)
2 20 (31.7%) 4 (40.0%) 5 (33.3%) 6 (42.9%) 0 3 (37.5%) 2 (28.6%)
3 or more 16 (25.4%) 3 (30.0%) 7 (46.7%) 2 (14.3%) 3 (33.3%) 1 (12.5%) 0 .117
Sites involved
Liver only 19 (30.2%) 3 (30.0%) 1 (6.7%) 3 (21.4%) 5 (55.6%) 4 (50.0%) 3 (42.9%)
Liver + other 29 (46.0%) 6 (60.0%) 10 (66.7%) 6 (42.9%) 2 (22.2%) 3 (37.5%) 2 (28.6%)
Other only 15 (23.8%) 1 (10.0%) 4 (26.7%) 5 (35.7%) 2 (22.2%) 1 (12.5%) 2 (28.6%) .245
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F I G U R E  3  Main chronoIFLO toxicities according to irinotecan timing and sex. A, Heat maps of percentages of male or female patients 
having developed grade 3-4 hematological or clinical toxicities over three or six cycles. B, Best fit cosine curves for percentages of men with grade 
3-4 neutropenia or anorexia over six cycles with respect to irinotecan timing. C, Best fit cosine curves for percentages of women with grade 3-4 
neutropenia or anorexia over six cycles with respect to irinotecan timing. D, Polar plots highlighting the sex-specific clock hours associated with 
minimum incidence of toxicities. For each toxicity, the arrow's length and angle represent amplitude and clock time of minimum value of the best-
fit cosine, respectively. Only toxicities with significant cosinor tests are displayed (P < .05)
A
B
D
C
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F I G U R E  4  Histograms depicting the incidence of the main severe toxicities over the initial six courses of chronoIFLO, in male or female 
patients as a function of peak delivery rate of irinotecan occurring in the morning (05:00 or 09:00), in the afternoon (13:00-17:00), or at night 
(21:00-01:00). A, Neutropenia (grades 3-4); B, Anemia (grades 2-4); C, Diarrhea (grades 3-4); D, Anorexia; (grades 3-4); E and F, Fatigue (grade 
3, and grades 2-3, respectively). The displayed p-values from Fisher's exact test correspond to the statistical significance of sex*timing interactions 
from Fisher's exact test for each endpoint
P = .0151 P = .0092
P = .0319P = .0238
P = .0625 P = .0245
A B
C D
E F
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tolerability was best in males but worst in females follow-
ing irinotecan peak delivery rate at 09:00. Irinotecan peak 
delivery rate at 13:00 or 17:00 resulted in best clinical toler-
ability in women.
Cosinor analysis revealed statistically significant circa-
dian rhythms in the proportions of patients with grade 3 
or 4 toxicities according to irinotecan timing for four end-
points in men, and for six of them in women (Figure 3B,C, 
Tables S2 and S3). Twenty-four hour or (24 + 12 hours) 
rhythms were found for neutropenia, leukopenia, and an-
orexia over six cycles both in men and in women, yet with 
distinct waveforms and circadian parameters. Thus, the 
double amplitudes were 9.1% in men vs 15.9% in women 
for leukopenia, 14.6% in men vs 38.3% in women for neu-
tropenia, and 18.9% in men vs 27.3% in women for an-
orexia (six courses). The least toxic timing of irinotecan 
peak delivery rate was located in the morning hours in 
men, being 07:55 for leukopenia, 9:04 for anorexia, and 
10:16 for neutropenia (six cycles). In women, the corre-
sponding optimal times were located in the afternoon, that 
is, 16:32, 14:59, and 15:06 (Figure 3D, Table S3). Female 
patients further displayed a (24 + 12-hours) rhythm in sto-
matitis and a 12-h rhythm in nausea. Optimal administra-
tion times were very consistent across all toxicity types 
for women, with times of minimum of simulated toxicity 
curves ranging from 14:48 to 16:03.
3.4 | Antitumor efficacy
Response rates, progression-free survival or overall sur-
vival did not differ according to sex or irinotecan peak de-
livery rate timing (Table S4), with overall respective figures 
of 56.7% [95% CL, 49.4 to 64.0], 8.4 months [7.5-9.3] and 
19.2 months [15.4-22.9].
Cosinor analysis did not show any significant rhythm for 
best overall response rates, response rates at first evaluation, 
progression-free survival or overall survival either in men 
(P = .41, .24, .32 or .29, respectively) or in women (P = .47, 
.16, .29, or .15, respectively).
3.5 | Practical implications for 
optimization of irinotecan timing
Statistically significant interactions between sex and tim-
ing of irinotecan peak delivery rate (morning vs afternoon 
vs night) were validated for the incidences of grades 2-4 
and grades 3-4 toxicities using Fisher's exact test (Figure 4). 
Overall, tolerability was best following peak delivery of iri-
notecan in the morning for males and in the afternoon for 
females.
In contrast, no significant difference was found regard-
ing progression-free survival or overall survival according to 
F I G U R E  5  Efficacy of chronoIFLO according to irinotecan timing in the morning, in the afternoon or at night in each sex. Progression-free 
survival curves in (A) male patients and (B) female patients. Overall survival curves according to irinotecan timing in (C) male patients and (D) 
female patients (see Table S3 for statistical comparisons)
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morning vs afternoon vs night timing of irinotecan both in 
male and in female patients (Figure 5).
4 |  DISCUSSION
The current study has revealed a sex-specific least toxic 
time of irinotecan administration with regard to objectively 
assessed neutropenia and other hematologic and clinical 
endpoints, in an international randomized trial, despite 
the least toxic time of administration of irinotecan could 
not be identified in the whole population. The incidence 
of severe neutropenia varied nearly threefold according to 
irinotecan timing in each sex. The least neutropenic dos-
ing time of irinotecan was located in the morning for men 
and in the afternoon for women. The other toxicity end-
points followed 24-hour variations that matched those of 
neutropenia, thus impacting on clinical tolerability, and 
treatment compliance. The magnitude of the time related 
differences in toxicities support the integration of optimal 
treatment timing specifications into the core of precision 
cancer medicine.1,30
Optimal irinotecan timing could theoretically be person-
alized even more accurately through systems medicine.1,31 
Thus, coupled experimental chronopharmacology data of 
irinotecan and their mathematical modeling have identi-
fied the main molecular clock determinants of chronotol-
erance.6,31 The dynamic assessment of circadian function 
before, during, and after chemotherapy administration, can 
further streamline such personalized chronotherapy through 
circadian biomarkers tele-monitoring.32-34 The safety of chro-
noIFLO delivery at home was recently highlighted, through 
the remote and continuous joint monitoring of circadian bio-
markers and patient-reported outcome measures with a dedi-
cated eHealth platform.34
The current trial has revealed that the patient's sex was 
an important factor that could alter optimal circadian tim-
ing of chemotherapy, thus confirming earlier findings with 
chronoFLO. Indeed, statistically significant differences 
according to sex were demonstrated for progression-free 
survival and overall survival in each of three international 
randomized Phase III trials and their meta-analysis in 842 
patients with metastatic colorectal cancer receiving fixed-
time chronoFLO. Men on this treatment protocol displayed 
both significantly less toxicity and significantly better sur-
vival, as compared to women on the same schedule, inde-
pendently from other prognostic factors.20,21 Suggestive 
evidence for an about 6-hour difference in optimal timing of 
chronoFLO between men and women was further provided 
in a time-finding clinical trial involving 114 patients. The 
daily timing of the chronoFLO schedule, that was here com-
bined with irinotecan, was on the average, the least toxic 
one for men, but not for women.22 The sex differences in the 
circadian patterns in chemotherapy tolerability were further 
supported by the demonstration of (a) sexual dimorphism 
in molecular circadian clock,35 (b) the molecular clock con-
trol of irinotecan cellular pharmacology,6 and (c) the sex 
dependency of irinotecan optimal timing and pharmacology 
in mice, resulting in a 4- to 6-hour delay in females as com-
pared to males.8,9,36,37 It was unlikely that sexual hormones 
played a major role in the sex-dependent differences in out-
comes, given the fact that the vast majority of women were 
postmenopausal, with a median age of 58 years. Conversely, 
sex-specific differences in both the endogenous circadian 
period and the phase angle of entrainment of circadian 
clocks have been evidenced in controlled laboratory studies 
in humans.38,39 Alongside sex-related circadian dissimilari-
ties, other biological differences between men and women, 
including immune system activity, body composition, phar-
macology of anticancer drugs, or the microbiome have been 
hypothesized as modulators of sex-dependent differences in 
treatment toxicity.40
A limitation in this study involves the post-hoc analysis of 
prospective data, with no a priori power calculation or strati-
fication based on sex subgroups. Notwithstanding, no signif-
icant differences in patients' characteristics were observed. 
Its strength lies on the validation of the hypothesis that was 
generated after the study had been completed, due to the sub-
sequent discovery of sex-specific optimal irinotecan timing 
in mice.8,9,36,37
In summary, this time-finding trial has identified sex-spe-
cific times for optimizing irinotecan tolerability, that is, in 
the morning hours for men, and in the afternoon hours for 
women. Such timing specifications deserve prospective val-
idation. ChronoIFLO delivery could readily be personalized 
thanks to mHealth platforms in the home setting, which allow 
for remote patients monitoring and real time determinations 
of individual circadian phase and patient condition.33,34,41-43 
The framework of systems pharmacology and systems med-
icine offers advanced mathematical means for optimizing 
chronotherapy according to molecular circadian clocks in 
individual patients.1
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